journal
Journals CA: a Cancer Journal for Clini...

CA: a Cancer Journal for Clinicians

https://read.qxmd.com/read/38481032/is-mandated-genetic-counseling-needed
#21
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38240706/most-patients-with-cancer-are-not-undergoing-germline-genetic-testing
#22
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38240705/more-care-needed-for-cancer-caregivers
#23
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/37909877/screening-for-lung-cancer-2023-guideline-update-from-the-american-cancer-society
#24
JOURNAL ARTICLE
Andrew M D Wolf, Kevin C Oeffinger, Tina Ya-Chen Shih, Louise C Walter, Timothy R Church, Elizabeth T H Fontham, Elena B Elkin, Ruth D Etzioni, Carmen E Guerra, Rebecca B Perkins, Karli K Kondo, Tyler B Kratzer, Deana Manassaram-Baptiste, William L Dahut, Robert A Smith
Lung cancer is the leading cause of mortality and person-years of life lost from cancer among US men and women. Early detection has been shown to be associated with reduced lung cancer mortality. Our objective was to update the American Cancer Society (ACS) 2013 lung cancer screening (LCS) guideline for adults at high risk for lung cancer. The guideline is intended to provide guidance for screening to health care providers and their patients who are at high risk for lung cancer due to a history of smoking. The ACS Guideline Development Group (GDG) utilized a systematic review of the LCS literature commissioned for the US Preventive Services Task Force 2021 LCS recommendation update; a second systematic review of lung cancer risk associated with years since quitting smoking (YSQ); literature published since 2021; two Cancer Intervention and Surveillance Modeling Network-validated lung cancer models to assess the benefits and harms of screening; an epidemiologic and modeling analysis examining the effect of YSQ and aging on lung cancer risk; and an updated analysis of benefit-to-radiation-risk ratios from LCS and follow-up examinations...
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/37909870/lung-cancer-diagnosis-and-mortality-beyond-15-years-since-quit-in-individuals-with-a-20-pack-year-history-a%C3%A2-systematic-review
#25
REVIEW
Karli K Kondo, Basmah Rahman, Chelsea K Ayers, Rose Relevo, Jessica C Griffin, Michael T Halpern
Current US lung cancer screening recommendations limit eligibility to adults with a pack-year (PY) history of ≥20 years and the first 15 years since quit (YSQ). The authors conducted a systematic review to better understand lung cancer incidence, risk and mortality among otherwise eligible individuals in this population beyond 15 YSQ. The PubMed and Scopus databases were searched through February 14, 2023, and relevant articles were searched by hand. Included studies examined the relationship between adults with both a ≥20-PY history and ≥15 YSQ and lung cancer diagnosis, mortality, and screening ineligibility...
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/37909861/screening-for-lung-cancer
#26
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
2024: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/38108561/opioid-analgesics-for-nociceptive-cancer-pain-a%C3%A2-comprehensive-review
#27
REVIEW
Christina Abdel Shaheed, Christopher Hayes, Christopher G Maher, Jane C Ballantyne, Martin Underwood, Andrew J McLachlan, Jennifer H Martin, Sujita W Narayan, Mark A Sidhom
Pain is one of the most burdensome symptoms in people with cancer, and opioid analgesics are considered the mainstay of cancer pain management. For this review, the authors evaluated the efficacy and toxicities of opioid analgesics compared with placebo, other opioids, nonopioid analgesics, and nonpharmacologic treatments for background cancer pain (continuous and relatively constant pain present at rest), and breakthrough cancer pain (transient exacerbation of pain despite stable and adequately controlled background pain)...
December 18, 2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/37962499/disparities-in-cancer-care-a-long-way-to-go
#28
EDITORIAL
Shail Maingi, Don S Dizon
No abstract text is available yet for this article.
November 14, 2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/37962495/american-cancer-society-s-report-on-the-status-of-cancer-disparities-in-the-united-states-2023
#29
JOURNAL ARTICLE
Farhad Islami, Jordan Baeker Bispo, Hyunjung Lee, Daniel Wiese, K Robin Yabroff, Priti Bandi, Kirsten Sloan, Alpa V Patel, Elvan C Daniels, Arif H Kamal, Carmen E Guerra, William L Dahut, Ahmedin Jemal
In 2021, the American Cancer Society published its first biennial report on the status of cancer disparities in the United States. In this second report, the authors provide updated data on racial, ethnic, socioeconomic (educational attainment as a marker), and geographic (metropolitan status) disparities in cancer occurrence and outcomes and contributing factors to these disparities in the country. The authors also review programs that have reduced cancer disparities and provide policy recommendations to further mitigate these inequalities...
November 14, 2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/37947355/testicular-cancer-in-2023-current-status-and-recent-progress
#30
REVIEW
Deaglan J McHugh, Jack P Gleeson, Darren R Feldman
Testicular germ cell tumor (GCT) is the most common solid tumor in adolescent and young adult men. Progress in the management of GCT has been made in the last 50 years, with a substantial improvement in cure rates for advanced disease, from 25% in the 1970s to nearly 80%. However, relapsed or platinum-refractory disease occurs in a proportion, 20% of whom will die from disease progression. This article reviews the current evidence-based treatments for extracranial GCT, the acute and chronic toxic effects that may result, and highlights contemporary advances and progress in the field...
November 10, 2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/37909864/lung-cancer-screening-guidelines-smoking-matters-not%C3%A2-quitting
#31
EDITORIAL
Don S Dizon, Arif H Kamal
No abstract text is available yet for this article.
November 1, 2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/37880100/immunosurveillance-in-clinical-cancer-management
#32
REVIEW
Guido Kroemer, Timothy A Chan, Alexander M M Eggermont, Lorenzo Galluzzi
The progression of cancer involves a critical step in which malignant cells escape from control by the immune system. Antineoplastic agents are particularly efficient when they succeed in restoring such control (immunosurveillance) or at least establish an equilibrium state that slows down disease progression. This is true not only for immunotherapies, such as immune checkpoint inhibitors (ICIs), but also for conventional chemotherapy, targeted anticancer agents, and radiation therapy. Thus, therapeutics that stress and kill cancer cells while provoking a tumor-targeting immune response, referred to as immunogenic cell death, are particularly useful in combination with ICIs...
October 25, 2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/37849051/locally-advanced-mismatch-repair-deficient-gastroesophageal-junction-cancer-diagnosis-treatment-modifications-and-monitoring
#33
JOURNAL ARTICLE
Rutika Mehta, Andrew Sinnamon, Aamir Dam, Christine Walko, Russell Palm, Laura Barton, Gregory Lauwers, Jose M Pimiento
No abstract text is available yet for this article.
October 17, 2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/36869429/cancer-survivors-at-greater-risk-for-bone-fractures-late-in-life
#34
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
March 2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/36869428/near-majority-of-adults-favor-r-ratings-for-films-with-smoking
#35
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
March 2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/36305841/consensuses-controversies-and-future-directions-in-treatment-deintensification-for-human-papillomavirus-associated-oropharyngeal-cancer
#36
REVIEW
Jung Julie Kang, Yao Yu, Linda Chen, Kaveh Zakeri, Daphna Yael Gelblum, Sean Matthew McBride, Nadeem Riaz, C Jillian Tsai, Anuja Kriplani, Tony K W Hung, James V Fetten, Lara A Dunn, Alan L Ho, Jay O Boyle, Ian S Ganly, Bhuvanesh Singh, Eric J Sherman, David G Pfister, Richard J Wong, Nancy Y Lee
The most common cancer caused by human papillomavirus (HPV) infection in the United States is oropharyngeal cancer (OPC), and its incidence has been rising since the turn of the century. Because of substantial long-term morbidities with chemoradiation and the favorable prognosis of HPV-positive OPC, identifying the optimal deintensification strategy for this group has been a keystone of academic head-and-neck surgery, radiation oncology, and medical oncology for over the past decade. However, the first generation of randomized chemotherapy deintensification trials failed to change the standard of care, triggering concern over the feasibility of de-escalation...
March 2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/36260350/advances-in-the-treatment-of-intrahepatic-cholangiocarcinoma-an-overview-of-the-current-and%C3%A2-future%C3%A2-therapeutic-landscape-for-clinicians
#37
REVIEW
Dimitrios Moris, Manisha Palta, Charles Kim, Peter J Allen, Michael A Morse, Michael E Lidsky
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and remains a fatal malignancy in the majority of patients. Approximately 20%-30% of patients are eligible for resection, which is considered the only potentially curative treatment; and, after resection, a median survival of 53 months has been reported when sequenced with adjuvant capecitabine. For the 70%-80% of patients who present with locally unresectable or distant metastatic disease, systemic therapy may delay progression, but survival remains limited to approximately 1 year...
March 2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/36149820/prevention-of-device-related-infections-in-patients-with-cancer-current-practice-and-future-horizons
#38
REVIEW
George M Viola, Ariel D Szvalb, Alexandre E Malek, Anne-Marie Chaftari, Ray Hachem, Issam I Raad
Over the past several years, multifaceted advances in the management of cancer have led to a significant improvement in survival rates. Throughout patients' oncological journeys, they will likely receive one or more implantable devices for the administration of fluids and medications as well as management of various comorbidities and complications related to cancer therapy. Infections associated with these devices are frequent and complex, often necessitating device removal, increasing health care costs, negatively affecting quality of life, and complicating oncological care, usually leading to delays in further life-saving cancer therapy...
March 2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/37924523/to-lower-cancer-risks-study-shows-that-food-choices-matter
#39
COMMENT
Mike Fillon
No abstract text is available yet for this article.
2023: CA: a Cancer Journal for Clinicians
https://read.qxmd.com/read/37924522/mced-blood-test-boosts-cancer-detection-in-symptomatic-patients
#40
JOURNAL ARTICLE
Mike Fillon
No abstract text is available yet for this article.
2023: CA: a Cancer Journal for Clinicians
journal
journal
20065
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.